Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
AstraZeneca
Medtronic
Express Scripts
Merck

Last Updated: January 27, 2023

Pegcetacoplan - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for pegcetacoplan and what is the scope of patent protection?

Pegcetacoplan is the generic ingredient in one branded drug marketed by Apellis Pharms and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegcetacoplan has one hundred and thirty-five patent family members in twenty-four countries.

Summary for pegcetacoplan
International Patents:135
US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Clinical Trials: 18
What excipients (inactive ingredients) are in pegcetacoplan?pegcetacoplan excipients list
DailyMed Link:pegcetacoplan at DailyMed
Recent Clinical Trials for pegcetacoplan

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Swedish Orphan BiovitrumPhase 2
Swedish Orphan BiovitrumPhase 3
Roswell Park Cancer InstitutePhase 2

See all pegcetacoplan clinical trials

US Patents and Regulatory Information for pegcetacoplan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for pegcetacoplan

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Swedish Orphan Biovitrum AB (publ) Aspaveli pegcetacoplan EMEA/H/C/005553
Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.,
Authorised no no yes 2021-12-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for pegcetacoplan

Country Patent Number Title Estimated Expiration
Croatia P20211342 See Plans and Pricing
Russian Federation 2012147267 ЭФФЕКТИВНЫЕ АНАЛОГИ КОМПСТАТИНА See Plans and Pricing
Hong Kong 1156862 COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY See Plans and Pricing
Russian Federation 2474586 ЭФФЕКТИВНЫЕ АНАЛОГИ КОМПСТАТИНА (EFFICIENT COMPSTATIN ANALOGUES) See Plans and Pricing
Japan 4614222 See Plans and Pricing
Serbia 62243 ANALOZI KOMPSTATINA SA PRODUŽENIM TRAJANJEM DEJSTVA I NJIHOVE KOMPOZICIJE I POSTUPCI (LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for pegcetacoplan

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3660033 122022000034 Germany See Plans and Pricing PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211213
3660033 PA2022010 Lithuania See Plans and Pricing PRODUCT NAME: PEGCETACOPLANAS ; REGISTRATION NO/DATE: EU/1/21/1595 20211213
3660033 CA 2022 00023 Denmark See Plans and Pricing PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214
3660033 301178 Netherlands See Plans and Pricing PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211214
3660033 2022C/522 Belgium See Plans and Pricing PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214
3660033 LUC00265 Luxembourg See Plans and Pricing PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Boehringer Ingelheim
McKesson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.